Expanding Ovarian Cancer Testing in South Africa
Battling cancer can be an overwhelming, sometimes impossible challenge, but it is not one that people always face alone. In western countries like the United States, accessibility to testing and treatment alike for a multitude of different cancers helps to catch them relatively quickly and perhaps send them into remission. However, this is not always the case in other countries/continents. South Africa in particular is victim to an inconsistent and partial healthcare system. As of 2025, only about 15.5% (less than 10 million) of South Africans currently have access to private healthcare. The other 84.5% (53 million people) pay out of pocket or rely on overwhelmed free clinics for care, including cancer testing. However, there is a new avenue of help for people to take. Here is information about how The Helix Project is expanding ovarian cancer testing in South Africa.
What is The Helix Project?
In August 2026, U.K. pharmaceutical giant AstraZeneca announced the creation and launch of The Helix Project, which is a multifaceted research initiative made up of several organizations, with a focus on disease prevention, drug development and genomic research. In South Africa, the project is working to expand ovarian cancer testing. For eligible patients, this will mean access to advanced genetic testing known as homologous recombination deficiency or HRD testing, which is used to identify signs of ovarian cancer earlier on in pre-diagnosed tumors by observing how cells repair double helix strands in DNA.
The project also aims to lower the overall cost of testing to the people of South Africa, and see faster diagnoses as a result. The actual pricing cuts for individual patients have not been specified yet, however, bringing together multiple international organizations, including the U.S. based Thermo Fisher Scientific, Ampath Global and South Africa’s own PathCare, the cost will be split into a “multi-stakeholder collaboration.”
The amount of new per-year ovarian cancer diagnoses in South Africa is growing, and oftentimes, in South Africa in particular, new cases are often diagnosed late. According to the current WHO Cancer Observatory figure, by 2050, the new yearly amount is set to rise by 78.8% from its previous 2024 evaluation of 1,361 cases. This means that over the next 25 years, tens of thousands of new cases will emerge, increasing by volume with each passing year. Additionally, many of the recorded cases are caught in the later stages of the disease, causing already high fatality rates. With 1,361 new positive cancer diagnoses in 2024, 1,039 passed away from the illness alongside them. The idea of the Helix Project is to detect early signs and prevent further stages of the cancer so it isn’t allowed to progress.
Metrics & Finances
As stated previously, the goal is to make HRD testing fast and affordable to eligible patients. This is important, because the last survey-based poverty data that South Africa’s Department of Statistics collected in 2023 showed that 40.8 million South Africans, nearly 67% of the entire country’s population, fall below the nation’s upper poverty line at R2,635 per month. Meanwhile, 10.8 million of them live below the food poverty line at R777 per month.
For context, genetic testing for all cancers in South Africa costs anywhere from R5,000 to R13,000 out of pocket. Additionally, before The Helix Project, HRD testing in particular was limited and among these expensive groupings. While those eligible patients diagnosed with ovarian cancer are a fraction of the overall population, statistics show that they are more likely to come from the greater impoverished population than outside of it, the majority of which fall under the 53 million South African citizens who are not currently enrolled with privatized healthcare or insurance in the country. While it is not impossible to afford, it can offer an obstacle for those with families to support every month, while time for ovarian cancer testing can be an important factor. The hope for this project is to make it an affordable reality, and to create a brighter future for those affected by this terrible affliction.
– Connor Seidel
Connor is based in Cambridge, MN, USA and focuses on Good News and Global Health for The Borgen Project.
Photo: Flickr
